{
    "root": "2fb10179-abf5-77e9-e063-6394a90aaf20",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Citalopram",
    "value": "20250306",
    "ingredients": [
        {
            "name": "COPOVIDONE K25-31",
            "code": "D9C330MD8B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_78913"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "CITALOPRAM HYDROBROMIDE",
            "code": "I1E9D14F36",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3724"
        }
    ],
    "indications": {
        "text": "citalopram indicated treatment major depressive disorder ( mdd ) adults [ ( 14 ) ] .",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "administer daily without food ( 2 ) . initial 20 mg daily ; one week may increase maximum 40 mg daily ( 2.1 ) . patients greater 60 years age , patients hepatic impairment , cyp2c19 poor metabolizers : maximum recommended 20 mg daily ( 2.2 ) . discontinuing citalopram , reduce gradually ( 2.4 , 5.6 ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "citalopram tablets , usp white , film coated , round , bi-convex tablets debossed left side bisect g right side bisect one side \u201c 208 \u201d ndc : 70518-2228-00 ndc : 70518-2228-01 ndc : 70518-2228-02 packaging : 30 1 blister pack packaging : 90 1 bottle plastic packaging : 30 1 bottle plastic storage handling citalopram tablets stored 20-25\u00b0c ( 68 77\u00b0f ) ; excursions permitted 15 30\u00b0c ( 59-86\u00b0f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "citalopram contraindicated patients : taking , within 14 days stopping , maois ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.3 ) , ( 7 ) ] . taking pimozide risk qt prolongation [ ( 7 ) ] . known hypersensitivity citalopram inactive ingredients citalopram . included angioedema anaphylaxis [ ( 6.2 ) ] .",
    "indications_original": "Citalopram is indicated for the treatment of major depressive disorder (MDD) in adults\n \n  [see Clinical Studies (\n  \n   14)]\n \n  .",
    "contraindications_original": "Administer once daily with or without food ( 2 ). Initial dosage is 20 mg once daily; after one week may increase to maximum dosage of 40 mg once daily ( 2.1 ). Patients greater than 60 years of age, patients with hepatic impairment, and CYP2C19 poor metabolizers: maximum recommended dosage is 20 mg once daily ( 2.2 ). When discontinuing Citalopram, reduce dosage gradually ( 2.4 , 5.6 ) .",
    "warningsAndPrecautions_original": "Citalopram Tablets, USP\n                  White, film coated, round, bi-convex tablets debossed with I on the left side of bisect and G on right side of bisect on one side and \u201c208\u201d on the other\n                  \n                  NDC: 70518-2228-00\n                  NDC: 70518-2228-01\n                  NDC: 70518-2228-02\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC\n                  \n                  Storage and Handling\n                  Citalopram tablets should be stored at 20-25\u00b0C (68 to 77\u00b0F); excursions permitted between 15 and 30\u00b0C (59-86\u00b0F) [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Citalopram is contraindicated in patients:\n                  \n                     taking, or within 14 days of stopping, MAOIs (including MAOIs such as linezolid or intravenous methylene blue) because of an increased risk of serotonin syndrome\n  \n   [see Warnings and Precautions (\n   \n    5.3), Drug Interactions (\n   \n    7)]\n  \n   .\n \n  \n                     taking pimozide because of risk of QT prolongation\n  \n   [see Drug Interactions (\n   \n    7)]\n  \n   .\n \n  \n                     with known hypersensitivity to citalopram or any of the inactive ingredients in Citalopram. Reactions have included angioedema and anaphylaxis\n  \n   [see Adverse Reactions (\n   \n    6.2)]\n  \n   .",
    "drug": [
        {
            "name": "Citalopram",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3723"
        }
    ]
}